Biggest News Aggregation in the World
📰 Therapeutic Development Programs News

Therapeutic Development Programs News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Therapeutic Development Programs. Real-time updates on events, politics, business and more.

Navidea Biopharmaceuticals (NYSE:NAVB) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note issued to investors on Thursday morning. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Trading Down 99.7 % NYSE NAVB opened at $0.00 on Thursday. The company has a 50 day moving average of $0.04 and […]
Navidea Biopharmaceuticals Inc Therapeutic Development Programs Navidea Biopharmaceuticals Free Report Biopharmaceuticals Trading Down Get Free Report

Navidea Biopharmaceuticals (NYSE:NAVB) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance Shares of NAVB opened at $0.00 on Thursday. Navidea Biopharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week […]
Navidea Biopharmaceuticals Inc Therapeutic Development Programs Navidea Biopharmaceuticals Free Report Get Free Report Diagnostic Substances

Navidea Biopharmaceuticals (NYSE:NAVB) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note released on Thursday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance Navidea Biopharmaceuticals has a twelve month low of $0.00 and a twelve month high of $0.17. The stock’s fifty day moving average price […]
Therapeutic Development Programs Navidea Biopharmaceuticals Inc Navidea Biopharmaceuticals Free Report Get Free Report Diagnostic Substances
Source: wkrb13.com

Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note released on Monday morning. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance Shares of NAVB opened at $0.04 on Monday. The company has a 50-day simple moving average of $0.04 and a 200-day simple […]
Therapeutic Development Programs Navidea Biopharmaceuticals Inc Navidea Biopharmaceuticals Company Profile Navidea Biopharmaceuticals Free Report Get Free Report

Navidea Biopharmaceuticals (NYSE:NAVB) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note issued to investors on Monday morning. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance Shares of NAVB stock opened at $0.04 on Monday. The stock’s fifty day moving average is $0.04 and its 200-day […]
Therapeutic Development Programs Navidea Biopharmaceuticals Inc Navidea Biopharmaceuticals Company Profile Navidea Biopharmaceuticals Free Report Get Free Report

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the stock. Navidea Biopharmaceuticals Stock Performance Navidea Biopharmaceuticals stock opened at $0.04 on Friday. Navidea Biopharmaceuticals has a twelve month low of […]
Therapeutic Development Programs Exchange Commission Navidea Biopharmaceuticals Inc Navidea Biopharmaceuticals Company Profile Navidea Biopharmaceuticals Get Free Report

StockNews.com Begins Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)

StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note issued to investors on Friday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance Shares of NAVB opened at $0.04 on Friday. The firm has a market capitalization of $3.95 million, a price-to-earnings ratio […]
Navidea Biopharmaceuticals Inc Renaissance Technologies Therapeutic Development Programs Exchange Commission Navidea Biopharmaceuticals Free Report
Source: wkrb13.com

Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note published on Thursday. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance Navidea Biopharmaceuticals stock opened at $0.04 on Thursday. The firm has a market capitalization of $4.09 million, a PE ratio of -0.68 and […]
Navidea Biopharmaceuticals Company Profile Navidea Biopharmaceuticals Inc Therapeutic Development Programs Navidea Biopharmaceuticals Free Report Get Free Report

Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report published on Wednesday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance NAVB opened at $0.06 on Wednesday. The stock has a market capitalization of $5.75 million, a price-to-earnings ratio of -0.96 and a beta of […]
Renaissance Technologies Navidea Biopharmaceuticals Company Profile Therapeutic Development Programs Allred Capital Management Navidea Biopharmaceuticals Inc Navidea Biopharmaceuticals
Source: wkrb13.com

Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report published on Wednesday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance Shares of NYSE:NAVB opened at $0.06 on Wednesday. The firm has a fifty day simple moving average of $0.06 and a two-hundred day simple […]
Renaissance Technologies Therapeutic Development Programs Allred Capital Management Navidea Biopharmaceuticals Inc Navidea Biopharmaceuticals Free Report

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science